Attachment_D_-_Price_Schedule.xlsx
XLSX spreadsheet 59 KB Posted
- Attached to
- CLIA Approved Proficiency Testing Federal contract opportunity
- Solicitation number
- 19-247-SOL-00001
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| Attachment_B_-_Scope_of_Work.pdf | ||
| Attachment_C_-_Provisions_&_Clauses.pdf | ||
| Attachment_A_-_SF1449.pdf | ||
| Attachment_E_-_Instruction_of_Offerors.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
MAIN LABORATORY
| LINE | PROGRAM CODE | DESCRIPTION | UNIT MEASURE | ANNUAL USAGE | UNIT PRICE | TOTAL |
| 1 | A2MG | Alpha-2 Macroglobulin | 1/EA | 1 | $ - 0 | $ - 0 |
| 2 | AAT | CAP/ACMG Alpha-1 Antitrypsin Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 3 | ABF1 | Automated Body Fluid | 1/EA | 1 | $ - 0 | $ - 0 |
| 4 | ABF2 | Automated Body Fluid | 1/EA | 1 | $ - 0 | $ - 0 |
| 5 | ABF3 | Automated Body Fluid | 1/EA | 1 | $ - 0 | $ - 0 |
| 6 | ABGIC | Accuracy Based Glucose, Insulin, and C-peptide | 1/EA | 1 | $ - 0 | $ - 0 |
| 7 | ABL | Accuracy-Based Lipids | 1/EA | 1 | $ - 0 | $ - 0 |
| 8 | ABOSG | ABO Subgroup Typing | 1/EA | 1 | $ - 0 | $ - 0 |
| 9 | ABS | Accuracy-Based Testosterone and Estradiol | 1/EA | 1 | $ - 0 | $ - 0 |
| 10 | ABT | Antibody Titer, Anti-A and Anti-D | 1/EA | 1 | $ - 0 | $ - 0 |
| 11 | ABT1 | Antibody Titer, Anti-A | 1/EA | 1 | $ - 0 | $ - 0 |
| 12 | ABT2 | Antibody Titer, Anti-D | 1/EA | 1 | $ - 0 | $ - 0 |
| 13 | ABT3 | Antibody Titer, Anti-B | 1/EA | 1 | $ - 0 | $ - 0 |
| 14 | ABTH | Harmonized Thyroid | 1/EA | 1 | $ - 0 | $ - 0 |
| 15 | ABU | Accuracy-Based Urine | 1/EA | 1 | $ - 0 | $ - 0 |
| 16 | ABVD | Accuracy-Based Vitamin D | 1/EA | 1 | $ - 0 | $ - 0 |
| 17 | ACA | Antichromatin Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 18 | ACE | Angiotensin Converting Enzyme | 1/EA | 1 | $ - 0 | $ - 0 |
| 19 | ACL | Antiphospholipid Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 20 | ADL | Aldolase | 1/EA | 1 | $ - 0 | $ - 0 |
| 21 | AFD | Antifungal Drugs Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 22 | AFL | Amniotic Fluid Leakage | 1/EA | 1 | $ - 0 | $ - 0 |
| 23 | AG | 1,5 Anhydroglucitol | 1/EA | 1 | $ - 0 | $ - 0 |
| 24 | AHIV | Anti-HIV 1/2 | 1/EA | 1 | $ - 0 | $ - 0 |
| 25 | AHIVW | Anti-HIV 1/2, Waived | 1/EA | 1 | $ - 0 | $ - 0 |
| 26 | AHT | Antihistone Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 27 | AL1 | CAP/AACC Whole Blood Alcohol/ Volatiles | 1/EA | 1 | $ - 0 | $ - 0 |
| 28 | AL2 | CAP/AACC Serum Alcohol/ Volatiles | 1/EA | 1 | $ - 0 | $ - 0 |
| 29 | AMH | Antimullerian Hormone | 1/EA | 1 | $ - 0 | $ - 0 |
| 30 | ANA | Antinuclear Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 31 | APC | Autoimmune Gastritis Markers | 1/EA | 1 | $ - 0 | $ - 0 |
| 32 | APOE | CAP/ACMG Apolipoprotein E Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 33 | APS | Antiphosphatidylserine Antibodies | 1/EA | 1 | $ - 0 | $ - 0 |
| 34 | APT | Fetal Hemoglobin | 1/EA | 1 | $ - 0 | $ - 0 |
| 35 | APXBN | Apixaban Anticoagulant Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 36 | AQ | Critical Care Blood Gas | 1/EA | 1 | $ - 0 | $ - 0 |
| 37 | AQ2 | Critical Care Blood Gas w/Chemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 38 | AQ2Q | Quality Cross Check-Blood Gas w/Chemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 39 | AQ3 | Critical Care Blood Gas, i-STAT | 1/EA | 1 | $ - 0 | $ - 0 |
| 40 | AQ3Q | Quality Cross Check-Blood Gas, i-STAT | 1/EA | 1 | $ - 0 | $ - 0 |
| 41 | AQ4 | Critical Care Blood Gas w/Chem, i-STAT | 1/EA | 1 | $ - 0 | $ - 0 |
| 42 | AQ4Q | Quality Cross Check- Bld Gas w/Chemistry i-STAT | 1/EA | 1 | $ - 0 | $ - 0 |
| 43 | AQQ | Quality Cross Check- Blood Gas | 1/EA | 1 | $ - 0 | $ - 0 |
| 44 | ARP | Antiribosomal P Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 45 | ASA | AntiSperm Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 46 | ASC | Anti-S. cerevisiae Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 47 | ASO | Antistreptolysin O | 1/EA | 1 | $ - 0 | $ - 0 |
| 48 | AUP | Autopsy Pathology | 1/EA | 1 | $ - 0 | $ - 0 |
| 49 | AUP1 | Autopsy Pathology, Additional Pathologist | 1/EA | 1 | $ - 0 | $ - 0 |
| 50 | B27 | HLA-B27 Typing | 1/EA | 1 | $ - 0 | $ - 0 |
| 51 | BALL | B-ALL Minimal Residual Disease | 1/EA | 1 | $ - 0 | $ - 0 |
| 52 | BCP | Blood Cell ID, Photographs | 1/EA | 1 | $ - 0 | $ - 0 |
| 53 | BCP2 | Blood Cell ID, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 54 | BCR | Bile Crystals | 1/EA | 1 | $ - 0 | $ - 0 |
| 55 | BCS | Blood Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 56 | BCS1 | Blood Culture, S. aureus | 1/EA | 1 | $ - 0 | $ - 0 |
| 57 | BDP | Bacterial Detection in Platelets, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 58 | BDP5 | Bacterial Detection in Platelets, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 59 | BDPV | Bacterial Detection in Platelets, Rapid, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 60 | BDPV5 | Bacterial Detection in Platelets, Rapid, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 61 | BFC | Body Fluid Crystals | 1/EA | 1 | $ - 0 | $ - 0 |
| 62 | BGL | CAP/ACMG Biochemical Genetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 63 | BGL1 | CAP/ACMG Carnitine, Qual/Quant | 1/EA | 1 | $ - 0 | $ - 0 |
| 64 | BGS | Bone and Growth | 1/EA | 1 | $ - 0 | $ - 0 |
| 65 | BL | CAP/AACC Blood Lead | 1/EA | 1 | $ - 0 | $ - 0 |
| 66 | BMD | Bone Marrow Cell Differential | 1/EA | 1 | $ - 0 | $ - 0 |
| 67 | BMV1 | 1,25 Dihydroxy Vitamin D | 1/EA | 1 | $ - 0 | $ - 0 |
| 68 | BMV2 | Bone-Specific Alkaline Phosphatase | 1/EA | 1 | $ - 0 | $ - 0 |
| 69 | BMV3 | Vitamin A | 1/EA | 1 | $ - 0 | $ - 0 |
| 70 | BMV4 | Viatmin E | 1/EA | 1 | $ - 0 | $ - 0 |
| 71 | BMV5 | C-Telopeptide | 1/EA | 1 | $ - 0 | $ - 0 |
| 72 | BMV6 | N-Telopeptide | 1/EA | 1 | $ - 0 | $ - 0 |
| 73 | BNP | B-Type Natriuretic Peptides, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 74 | BNP5 | B-Type Natriuretic Peptides, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 75 | BNPQ | Quality Cross Check - BNP | 1/EA | 1 | $ - 0 | $ - 0 |
| 76 | BOR | B. pertussis/parapertussis, Molecular | 1/EA | 1 | $ - 0 | $ - 0 |
| 77 | BP | Blood Parasite | 1/EA | 1 | $ - 0 | $ - 0 |
| 78 | BRAF | BRAF | 1/EA | 1 | $ - 0 | $ - 0 |
| 79 | BRAFV | BRAF V600EIHC | 1/EA | 1 | $ - 0 | $ - 0 |
| 80 | BRCA | CAP/ACMG BRCA 1/2 Sequencing | 1/EA | 1 | $ - 0 | $ - 0 |
| 81 | BSTS | Bact Strain Typing, Staphylococcus | 1/EA | 1 | $ - 0 | $ - 0 |
| 82 | BU | Bone and Mineral Metabolism, Urine | 1/EA | 1 | $ - 0 | $ - 0 |
| 83 | BV | Bacterial Vaginosis | 1/EA | 1 | $ - 0 | $ - 0 |
| 84 | C1 | Chemistry - General, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 85 | C3 | Chemistry - General, Comprehensive | 1/EA | 1 | $ - 0 | $ - 0 |
| 86 | C3X | Chemistry - General, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 87 | C4 | Chemistry - Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 88 | C7 | Pseudocholinesterase | 1/EA | 1 | $ - 0 | $ - 0 |
| 89 | CAMP | Campylobacter | 1/EA | 1 | $ - 0 | $ - 0 |
| 90 | CBT* | Cord Blood Testing | 1/EA | 1 | $ - 0 | $ - 0 |
| 91 | CCP | Cyclic Citrullinated Peptide Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 92 | CD | Cadmium | 1/EA | 1 | $ - 0 | $ - 0 |
| 93 | CD30 | CD30 Immunohistochemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 94 | CDF2 | C. diff, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 95 | CDF5 | C. diff, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 96 | CES | Celiac Serology | 1/EA | 1 | $ - 0 | $ - 0 |
| 97 | CESX | Celiac Serology, Additional Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 98 | CFDNA | Cell-Free DNA | 1/EA | 1 | $ - 0 | $ - 0 |
| 99 | CGB | Coagulation, Basic | 1/EA | 1 | $ - 0 | $ - 0 |
| 100 | CGDF | D-dimer/FDP | 1/EA | 1 | $ - 0 | $ - 0 |
| 101 | CGE | Coagulation, Extended | 1/EA | 1 | $ - 0 | $ - 0 |
| 102 | CGEX | Coagulation-Extended, Additional Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 103 | CGL | Coagulation, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 104 | CGLQ | Quality Cross Check—Coagulation | 1/EA | 1 | $ - 0 | $ - 0 |
| 105 | CGM | Coagulation-Limited, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 106 | CGS1 | Lupus Anticoagulant and Mixing Studies | 1/EA | 1 | $ - 0 | $ - 0 |
| 107 | CGS2 | Thrombophilia | 1/EA | 1 | $ - 0 | $ - 0 |
| 108 | CGS3 | von Willebrand Factor | 1/EA | 1 | $ - 0 | $ - 0 |
| 109 | CGS4 | Heparin | 1/EA | 1 | $ - 0 | $ - 0 |
| 110 | CGS5 | Heparin-Induced Thrombocytopenia | 1/EA | 1 | $ - 0 | $ - 0 |
| 111 | CGS6 | Heparin-Induced Thrombocytopenia | 1/EA | 1 | $ - 0 | $ - 0 |
| 112 | CGS7 | ADAMTS13 | 1/EA | 1 | $ - 0 | $ - 0 |
| 113 | CGS8 | Heparin-Induced Thrombocytopenia | 1/EA | 1 | $ - 0 | $ - 0 |
| 114 | CH50 | Total Hemolytic Complement | 1/EA | 1 | $ - 0 | $ - 0 |
| 115 | CHPVD | Human Papillomavirus, Digene | 1/EA | 1 | $ - 0 | $ - 0 |
| 116 | CHPVJ | Human Papillomavirus, Mixed Media | 1/EA | 1 | $ - 0 | $ - 0 |
| 117 | CHPVK | Human Papillomavirus, SurePath | 1/EA | 1 | $ - 0 | $ - 0 |
| 118 | CHPVM | Human Papillomavirus, ThinPrep | 1/EA | 1 | $ - 0 | $ - 0 |
| 119 | CMMP | Clinical Microscopy Miscellaneous Photopage | 1/EA | 1 | $ - 0 | $ - 0 |
| 120 | CMP | Urinalysis w/Body Fluid & Urine Sediment Photos | 1/EA | 1 | $ - 0 | $ - 0 |
| 121 | CMP1 | iChem Urinalysis w/Body Fluid & Urine Sediment Photos | 1/EA | 1 | $ - 0 | $ - 0 |
| 122 | CMQ | Quality Cross Check—Urinalysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 123 | CMSP | CAP/ACMG Cardiomyopathy Sequencing Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 124 | CPIP | Clinical Pathology Improvement Program | 1/EA | 1 | $ - 0 | $ - 0 |
| 125 | CPIP1 | Clinical Pathology Improvement Program, Additional Participant | 1/EA | 1 | $ - 0 | $ - 0 |
| 126 | CRO | Carbopenem Resistant Organisms | 1/EA | 1 | $ - 0 | $ - 0 |
| 127 | CRP | C-Reactive Protein | 1/EA | 1 | $ - 0 | $ - 0 |
| 128 | CRT | Cardiac Markers | 1/EA | 1 | $ - 0 | $ - 0 |
| 129 | CRTI | Cardiac Markers, Isoenzymes & Troponin I | 1/EA | 1 | $ - 0 | $ - 0 |
| 130 | CRYP | Cryptococcal Antigen Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 131 | CS | CAP/AACC Immunosuppressive Drugs | 1/EA | 1 | $ - 0 | $ - 0 |
| 132 | CT | Activated Clotting Time | 1/EA | 1 | $ - 0 | $ - 0 |
| 133 | CT1 | Activated Clotting Time | 1/EA | 1 | $ - 0 | $ - 0 |
| 134 | CT1Q | Quality Cross Check—ACT | 1/EA | 1 | $ - 0 | $ - 0 |
| 135 | CT2 | Activated Clotting Time | 1/EA | 1 | $ - 0 | $ - 0 |
| 136 | CT2Q | Quality Cross Check—ACT | 1/EA | 1 | $ - 0 | $ - 0 |
| 137 | CT3 | Activated Clotting Time | 1/EA | 1 | $ - 0 | $ - 0 |
| 138 | CT3Q | Quality Cross Check—ACT | 1/EA | 1 | $ - 0 | $ - 0 |
| 139 | CT5 | Activated Clotting Time | 1/EA | 1 | $ - 0 | $ - 0 |
| 140 | CT5Q | Quality Cross Check—ACT | 1/EA | 1 | $ - 0 | $ - 0 |
| 141 | CTKN | Cytokines | 1/EA | 1 | $ - 0 | $ - 0 |
| 142 | CTQ | Quality Cross Check—ACT | 1/EA | 1 | $ - 0 | $ - 0 |
| 143 | CY | CAP/ACMG Cytogenetics, Online Images | 1/EA | 1 | $ - 0 | $ - 0 |
| 144 | CYBK | CAP/ACMG Cytogenetics, Booklet | 1/EA | 1 | $ - 0 | $ - 0 |
| 145 | CYCGH | CAP/ACMG Constitutional Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 146 | CYCMA | CAP/ACMG Oncologic Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 147 | CYF | CAP/ACMG FISH Constitutional/Hematologic Disorders | 1/EA | 1 | $ - 0 | $ - 0 |
| 148 | CYH | CAP/ACMG FISH, Paraffin-Embedded Tissue | 1/EA | 1 | $ - 0 | $ - 0 |
| 149 | CYI | CAP/ACMG FISH, Urothelial Carcinoma | 1/EA | 1 | $ - 0 | $ - 0 |
| 150 | CYJ | CAP/ACMG FISH, Paraffin-Embedded Tissue | 1/EA | 1 | $ - 0 | $ - 0 |
| 151 | CYK | CAP/ACMG FISH, Paraffin-Embedded Tissue | 1/EA | 1 | $ - 0 | $ - 0 |
| 152 | CYL | CAP/ACMG FISH, Paraffin-Embedded Tissue | 1/EA | 1 | $ - 0 | $ - 0 |
| 153 | CYS | Cystatin C | 1/EA | 1 | $ - 0 | $ - 0 |
| 154 | CZ | Chemistry/Therapeutic Drug Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 155 | CZ2X | Chemistry/TDM, Triple Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 156 | CZQ | Quality Cross Check - Chemistry/Therapeutic Drug Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 157 | CZVM | Chemistry/TDM, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 158 | CZX | Chemistry/TDM, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 159 | D | Bacteriology | 1/EA | 1 | $ - 0 | $ - 0 |
| 160 | D1 | Throat Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 161 | D2 | Urine Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 162 | D3 | N. gonorrhoeae Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 163 | D4 | Bacteriology, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 164 | D5 | Gram Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 165 | D6 | Rapid Group A Strep Antigen Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 166 | D7 | Throat/Urine Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 167 | D8 | Group B Strep Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 168 | D9 | Rapid Group A Strep Antigen Detection, Waived | 1/EA | 1 | $ - 0 | $ - 0 |
| 169 | DADR1 | HLA Disease Association-Drug Risk | 1/EA | 1 | $ - 0 | $ - 0 |
| 170 | DADR2 | HLA Disease Association-Drug Risk | 1/EA | 1 | $ - 0 | $ - 0 |
| 171 | DAI | Urine Drug Adulterant/Integrity | 1/EA | 1 | $ - 0 | $ - 0 |
| 172 | DAT | Direct Antiglobulin Testing | 1/EA | 1 | $ - 0 | $ - 0 |
| 173 | DBGN | Dabigatran Anticoagulant Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 174 | DEX | Expanded Bacteriology | 1/EA | 1 | $ - 0 | $ - 0 |
| 175 | DFC | Drug-Facilitated Crime | 1/EA | 1 | $ - 0 | $ - 0 |
| 176 | DML | Class I & II HLA Molecular Typing | 1/EA | 1 | $ - 0 | $ - 0 |
| 177 | DMPM | Drug Monitoring for Pain Management | 1/EA | 1 | $ - 0 | $ - 0 |
| 178 | DPATH | Digital Slide Program - Dermatopathology | 1/EA | 1 | $ - 0 | $ - 0 |
| 179 | DPATH1 | Digital Slide Program - Dermatopathology, Additional Pathologist | 1/EA | 2 | $ - 0 | $ - 0 |
| 180 | DSC | Dipstick Confirmatory Testing | 1/EA | 1 | $ - 0 | $ - 0 |
| 181 | DY | Ligand Assay - Testosterone, SHBG | 1/EA | 1 | $ - 0 | $ - 0 |
| 182 | E | Mycobacteriology | 1/EA | 1 | $ - 0 | $ - 0 |
| 183 | E1 | Mycobacteriology, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 184 | EGFR | EGFR | 1/EA | 1 | $ - 0 | $ - 0 |
| 185 | EHE1 | Expanded Virtual Peripheral Blood Smear | 1/EA | 1 | $ - 0 | $ - 0 |
| 186 | ELU | Eluate | 1/EA | 1 | $ - 0 | $ - 0 |
| 187 | EMB | Embryology | 1/EA | 1 | $ - 0 | $ - 0 |
| 188 | EPO | Erythropoietin | 1/EA | 1 | $ - 0 | $ - 0 |
| 189 | ESR | Erythrocyte Sedimentation Rate | 1/EA | 1 | $ - 0 | $ - 0 |
| 190 | ESR1 | Erythrocyte Sedimentation Rate | 1/EA | 1 | $ - 0 | $ - 0 |
| 191 | ESR2 | Erythrocyte Sedimentation Rate | 1/EA | 1 | $ - 0 | $ - 0 |
| 192 | ESR3 | Erythrocyte Sedimentation Rate | 1/EA | 1 | $ - 0 | $ - 0 |
| 193 | ETB | Ethanol Biomarkers | 1/EA | 1 | $ - 0 | $ - 0 |
| 194 | ETME1 | Expanded Transfusion Medicine Exercises | 1/EA | 1 | $ - 0 | $ - 0 |
| 195 | EV | Everolimus | 1/EA | 1 | $ - 0 | $ - 0 |
| 196 | EXM | Electronic Crossmatch | 1/EA | 1 | $ - 0 | $ - 0 |
| 197 | EXM2 | Electronic Crossmatch, Automated | 1/EA | 1 | $ - 0 | $ - 0 |
| 198 | F | Mycology and Aerobic Actinomycetes | 1/EA | 1 | $ - 0 | $ - 0 |
| 199 | F1 | Yeast | 1/EA | 1 | $ - 0 | $ - 0 |
| 200 | F3 | Candida Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 201 | FCAL | Fecal Calprotectin | 1/EA | 1 | $ - 0 | $ - 0 |
| 202 | FCFS | Fecal Fat | 1/EA | 1 | $ - 0 | $ - 0 |
| 203 | FCN | Antifilamentous Actin IgG Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 204 | FF | Fetal Fibronectin | 1/EA | 1 | $ - 0 | $ - 0 |
| 205 | FGAL | Galactomannan | 1/EA | 1 | $ - 0 | $ - 0 |
| 206 | FH1 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 207 | FH1P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 208 | FH2 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 209 | FH2P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 210 | FH3 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 211 | FH3P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 212 | FH3Q | Quality Cross Check - Hematology | 1/EA | 1 | $ - 0 | $ - 0 |
| 213 | FH4 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 214 | FH4P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 215 | FH4Q | Quality Cross Check - Hematology | 1/EA | 1 | $ - 0 | $ - 0 |
| 216 | FH6 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 217 | FH6P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 218 | FH6Q | Quality Cross Check—Hematology | 1/EA | 1 | $ - 0 | $ - 0 |
| 219 | FH9 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 220 | FH9P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 221 | FH9Q | Quality Cross Check—Hematology | 1/EA | 1 | $ - 0 | $ - 0 |
| 222 | FH10 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 223 | FH10P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 224 | FH13 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 225 | FH13P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 226 | FH14 | Hematology Automated Differential Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 227 | FH14P | Hematology Automated Differential Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 228 | FH15 | Centrifugal Hematology | 1/EA | 1 | $ - 0 | $ - 0 |
| 229 | FL | Flow Cytometry Combo (FL1/FL2) | 1/EA | 1 | $ - 0 | $ - 0 |
| 230 | FL1 | Flow Cytometry, Lymphocyte Phenotype | 1/EA | 1 | $ - 0 | $ - 0 |
| 231 | FL2 | Flow Cytometry, DNA Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 232 | FL3 | Flow Immunophen Leukemia/Lymphoma | 1/EA | 1 | $ - 0 | $ - 0 |
| 233 | FL4 | Flow Cytometry, CD34+ | 1/EA | 1 | $ - 0 | $ - 0 |
| 234 | FL5 | Flow Cytometry, Interpretation Only | 1/EA | 1 | $ - 0 | $ - 0 |
| 235 | FLAC | Fecal Lactoferrin | 1/EA | 1 | $ - 0 | $ - 0 |
| 236 | FLD | Body Fluid Chemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 237 | FLD2 | Body Fluid Chemistry 2 | 1/EA | 1 | $ - 0 | $ - 0 |
| 238 | FLDQ | Quality Cross Check—Body Fluid Chemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 239 | FNA | Digital Slide Program in Fine-Needle Aspiration | 1/EA | 1 | $ - 0 | $ - 0 |
| 240 | FNA1 | Digital Slide Program in Fine-Needle Aspiration, Individual | 1/EA | 1 | $ - 0 | $ - 0 |
| 241 | FNAG | Fine-Needle Aspiration Glass Slides, Laboratory | 1/EA | 1 | $ - 0 | $ - 0 |
| 242 | FNAG1 | Fine-Needle Aspiration Glass Slides, Individual | 1/EA | 2 | $ - 0 | $ - 0 |
| 243 | FNPX | Fondaparinux Anticoagulant Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 244 | FOL | RBC Folate | 1/EA | 1 | $ - 0 | $ - 0 |
| 245 | FP | Second Trimester Maternal Screening | 1/EA | 1 | $ - 0 | $ - 0 |
| 246 | FP1B | First Trimester Maternal Screen, Free Beta | 1/EA | 1 | $ - 0 | $ - 0 |
| 247 | FP1T | First Trimester Maternal Screen, Total Beta | 1/EA | 1 | $ - 0 | $ - 0 |
| 248 | FPX | Second Trimester Maternal Screening, Additional Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 249 | FR | Forensic Pathology | 1/EA | 1 | $ - 0 | $ - 0 |
| 250 | FR1 | Forensic Pathology, Additional Pathologist | 1/EA | 1 | $ - 0 | $ - 0 |
| 251 | FSER | Fungai Serology | 1/EA | 1 | $ - 0 | $ - 0 |
| 252 | FSM | Fungail Smear | 1/EA | 1 | $ - 0 | $ - 0 |
| 253 | FT | Fructosamine | 1/EA | 1 | $ - 0 | $ - 0 |
| 254 | FTC | Forensic Toxicology, Criminalistics | 1/EA | 1 | $ - 0 | $ - 0 |
| 255 | G | Syphilis Serology | 1/EA | 1 | $ - 0 | $ - 0 |
| 256 | G6PDS | Glucose-6-Phosphate Dehydrogenase | 1/EA | 1 | $ - 0 | $ - 0 |
| 257 | GH2 | Hemoglobin A1c, 3 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 258 | GH5 | Hemoglobin A1c, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 259 | GH5I | Hemoglobin A1c, Internationl | 1/EA | 1 | $ - 0 | $ - 0 |
| 260 | GHER2 | Gastric HER2 | 1/EA | 1 | $ - 0 | $ - 0 |
| 261 | GHQ | Quality Cross Check—Hemoglobin A1c | 1/EA | 3 | $ - 0 | $ - 0 |
| 262 | GIP | Gastrointestinal Panel, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 263 | GIP5 | Gastrointestinal Panel, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 264 | GLI | Glioma | 1/EA | 1 | $ - 0 | $ - 0 |
| 265 | GNBC | Gram-Negative Blood Culture Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 266 | GOCB | Gastric Occult Blood | 1/EA | 1 | $ - 0 | $ - 0 |
| 267 | GPBC | Gram-Positive Blood Culture Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 268 | GSA | Glycated Serum Albumin | 1/EA | 1 | $ - 0 | $ - 0 |
| 269 | H | Antimitochondrial M2 Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 270 | HBF | Fetal Red Cell Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 271 | HBVL | Hepatitis B Viral Load, 3 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 272 | HBVL5 | Hepatitis B Viral Load, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 273 | HC1 | C. trachomatis Antigen (DFA) Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 274 | HC2 | Herpes Simplex, Antigen Detection (DFA) | 1/EA | 1 | $ - 0 | $ - 0 |
| 275 | HC3 | C. trachomatis Antigen Detection (EIA) | 1/EA | 1 | $ - 0 | $ - 0 |
| 276 | HC4 | Herpes Simplex Virus, Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 277 | HC6 | C. trachomatis/N. gonorrhoeae by Nucleic Acid Amplification (NAA) | 1/EA | 1 | $ - 0 | $ - 0 |
| 278 | HC6X | C. trachomatis/N. gonorrhoeae by Nucleic Acid Amplification (NAA), Additional Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 279 | HC7 | C. trachomatis/N. gonorrhoeae with DNA | 1/EA | 1 | $ - 0 | $ - 0 |
| 280 | HCC | Waived Combination | 1/EA | 1 | $ - 0 | $ - 0 |
| 281 | HCC2 | Waived Combination | 1/EA | 1 | $ - 0 | $ - 0 |
| 282 | HCG | HCG, Serum | 1/EA | 1 | $ - 0 | $ - 0 |
| 283 | HCV2 | Hepatitis C Viral Load | 1/EA | 1 | $ - 0 | $ - 0 |
| 284 | HE | Hematology - Basic | 1/EA | 1 | $ - 0 | $ - 0 |
| 285 | HEP | Hematology - Basic with Blood Cell ID | 1/EA | 1 | $ - 0 | $ - 0 |
| 286 | HER2* | HER2 Immunohistochemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 287 | HFC | Hemocytometer Fluid Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 288 | HFCI | Hemocytometer Fluid count, Internationl | 1/EA | 1 | $ - 0 | $ - 0 |
| 289 | HG | Hemoglobinopathy | 1/EA | 1 | $ - 0 | $ - 0 |
| 290 | HGM | CAP/ACMG Hemoglobinopathies Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 291 | HIVG | HIV Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 292 | HMS | Homocysteine | 1/EA | 1 | $ - 0 | $ - 0 |
| 293 | HPATH | Hematopathology Online Education | 1/EA | 1 | $ - 0 | $ - 0 |
| 294 | HPATH1 | Hematopathology Online Education, Each Additional Participant | 1/EA | 1 | $ - 0 | $ - 0 |
| 295 | HPS | H.pylori Antigen, Stool | 1/EA | 1 | $ - 0 | $ - 0 |
| 296 | HPV | Human Papillomavirus | 1/EA | 1 | $ - 0 | $ - 0 |
| 297 | HQBX1 | CAP/NSH Gastrointestinal Biopsy | 1/EA | 1 | $ - 0 | $ - 0 |
| 298 | HQBX2 | CAP/NSH Dermatologic Biopsy | 1/EA | 1 | $ - 0 | $ - 0 |
| 299 | HQBX3 | CAP/NSH Urogenital Biopsy | 1/EA | 1 | $ - 0 | $ - 0 |
| 300 | HQBX4 | CAP/NSH Gynecologic Biopsy | 1/EA | 1 | $ - 0 | $ - 0 |
| 301 | HQIHC | CAP/NSH HistoQIP Immunohistochemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 302 | HQIP | CAP/NSH HISTOQIP | 1/EA | 1 | $ - 0 | $ - 0 |
| 303 | HQIPBX | CAP/NSH HISTOQIP Biopsy Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 304 | HQMMR | CAP/NSH HistoQIP Mismatch Repair IHC | 1/EA | 1 | $ - 0 | $ - 0 |
| 305 | HQNSC | HQIP Non-small Cell Lung Carcinoma IHC | 1/EA | 1 | $ - 0 | $ - 0 |
| 306 | HQWSI | HQIP Whole Slide Image Quality Improvement Program | 1/EA | 1 | $ - 0 | $ - 0 |
| 307 | HSCRP | High Sensitivity C-Reactive Protein | 1/EA | 1 | $ - 0 | $ - 0 |
| 308 | HUEP | Human Epididymis Protein 5 | 1/EA | 1 | $ - 0 | $ - 0 |
| 309 | HV2 | HIV Viral Load | 1/EA | 1 | $ - 0 | $ - 0 |
| 310 | I | Instrumentation | 1/EA | 1 | $ - 0 | $ - 0 |
| 311 | ICSP | CAP/ACMG Inherited Cancer Sequencing Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 312 | ID1 | Nucleic Acid Amplification, Viruses | 1/EA | 1 | $ - 0 | $ - 0 |
| 313 | ID1T | Nucleic Acid Amplification, JC & BK | 1/EA | 1 | $ - 0 | $ - 0 |
| 314 | ID2 | Nucleic Acid Amplification, Respiratory | 1/EA | 1 | $ - 0 | $ - 0 |
| 315 | ID3 | Influenza A, Influenza B, and RSV by NAA | 1/EA | 1 | $ - 0 | $ - 0 |
| 316 | IDME | Meningitis/Encephalitis Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 317 | IDN | NAA, Organisms Without MTB | 1/EA | 1 | $ - 0 | $ - 0 |
| 318 | IDO | Nucleic Acid Amplification, Organisms | 1/EA | 1 | $ - 0 | $ - 0 |
| 319 | IDR | Infectious Disease, Respiratory Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 320 | IFS | Interfering Substances | 1/EA | 1 | $ - 0 | $ - 0 |
| 321 | IG | Immunology - General | 1/EA | 1 | $ - 0 | $ - 0 |
| 322 | IGHV | IGHV Mutation Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 323 | IGX | Immunology - General, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 324 | IL | Immunology - Comprehensive | 1/EA | 1 | $ - 0 | $ - 0 |
| 325 | IM | Infectious Mononucleosis | 1/EA | 1 | $ - 0 | $ - 0 |
| 326 | IMD1 | CAP/ACMG Mitochondrial DNA Deletion Syndrome | 1/EA | 1 | $ - 0 | $ - 0 |
| 327 | IMD2 | CAP/ACMG MCAD | 1/EA | 1 | $ - 0 | $ - 0 |
| 328 | IMD3 | CAP/ACMG Mitochondrial Cytopathies | 1/EA | 1 | $ - 0 | $ - 0 |
| 329 | IMW | Infectious Mononucleosis, Waived | 1/EA | 1 | $ - 0 | $ - 0 |
| 330 | IND | India Ink | 1/EA | 1 | $ - 0 | $ - 0 |
| 331 | ING | Insulin, Gastrin, C-Peptide, and PTH | 1/EA | 1 | $ - 0 | $ - 0 |
| 332 | ISH | In Situ Hybridization | 1/EA | 1 | $ - 0 | $ - 0 |
| 333 | ISH2 | In Situ Hybridization, HER2 (ERBB2) | 1/EA | 1 | $ - 0 | $ - 0 |
| 334 | J | Transfusion Medicine - Comprehensive | 1/EA | 1 | $ - 0 | $ - 0 |
| 335 | J1 | Transfusion Medicine - Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 336 | JAT | Transfusion Medicine - Automated | 1/EA | 1 | $ - 0 | $ - 0 |
| 337 | JATE1 | Transfusion Medicine - Automated Educational Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 338 | JATQ | Quality Cross Check - Transfusion Medicine | 1/EA | 1 | $ - 0 | $ - 0 |
| 339 | JE1 | Transfusion Medicine - Educational Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 340 | K | Ligand - General | 1/EA | 1 | $ - 0 | $ - 0 |
| 341 | K2 | Ligand - Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 342 | KET | Ketones | 1/EA | 1 | $ - 0 | $ - 0 |
| 343 | KIT | KIT/PDGFRA | 1/EA | 1 | $ - 0 | $ - 0 |
| 344 | KK | Ligand - General, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 345 | KRAS | KRAS | 1/EA | 1 | $ - 0 | $ - 0 |
| 346 | KSA | Kidney Stone Assessment | 1/EA | 1 | $ - 0 | $ - 0 |
| 347 | KVM | Ligand Assay - General, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 348 | LBAS | Legionella Antigen Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 349 | LBC | Lamellar Body Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 350 | LCW | Chemistry Limited, Waived | 1/EA | 1 | $ - 0 | $ - 0 |
| 351 | LKM | Liver-Kidney Microsomal Antibody | 1/EA | 1 | $ - 0 | $ - 0 |
| 352 | LN2 | Chemistry, Lipid, Enzyme Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 353 | LN2BV | chem CVL Beck (Except AU), Vitros Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 354 | LN3 | Therapeutic Drug Monitoring Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 355 | LN5 | Ligand Assay Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 356 | LN5S | Ligand Assay, Siemens Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 357 | LN6 | Urine Chemistry Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 358 | LN7 | Immunology Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 359 | LN8 | Reproductive Endocrinology Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 360 | LN9 | Hematology Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 361 | LN11 | Serum Ethanol Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 362 | LN12 | C-Reactive Protein Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 363 | LN12E | C-Reactive Protein, Extended Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 364 | LN13 | Blood Gas Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 365 | LN13C | Blood Gas /Critical Care Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 366 | LN15 | Hemoglobin A, Accuracy Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 367 | LN16 | Homocysteine Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 368 | LN17 | Whole Blood Glucose Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 369 | LN18 | Reticulocyte Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 370 | LN19 | Reticulocyte Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 371 | LN20 | Urine Albumin Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 372 | LN21 | High-Sensitivity CRP Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 373 | LN22 | Flow Cytometry Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 374 | LN23 | Prostate-Specific Antigen Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 375 | LN24 | Creatinine Accuracy Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 376 | LN25 | Troponin I Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 377 | LN27 | Troponin T Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 378 | LN30 | B-Type Natriuretic Peptide Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 379 | LN31 | Immunosuppressive Drugs Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 380 | LN32 | Ammonia Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 381 | LN33 | Serum Myoglobin Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 382 | LN34 | Tumor Markers Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 383 | LN35 | Thrombophilia Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 384 | LN36 | Heparin Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 385 | LN37 | von Willebrand Factor Antigen Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 386 | LN38 | CMV Viral Load Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 387 | LN39 | HIV Viral Load Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 388 | LN40 | Vitamin D Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 389 | LN41 | Procalcitonin Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 390 | LN42 | D-Dimer Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 391 | LN43 | Lamellar Body Count Calibration Verification/Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 392 | LN44 | Fibrinogen Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 393 | LN45 | HCV Viral Load Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 394 | LN46 | C-Peptide/Insulin Calibration Verification/ Linearity | 1/EA | 1 | $ - 0 | $ - 0 |
| 395 | LPE | Lipoprotein Electrophoresis | 1/EA | 1 | $ - 0 | $ - 0 |
| 396 | LPX | Laboratory Preparedness Exercise | 1/EA | 1 | $ - 0 | $ - 0 |
| 397 | M | Cerebrospinal Fluid Chemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 398 | MBT | Micro Bench Tools Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 399 | MC1 | Microbiology - Combination w/GC | 1/EA | 1 | $ - 0 | $ - 0 |
| 400 | MC2 | Microbiology - Combination | 1/EA | 1 | $ - 0 | $ - 0 |
| 401 | MC3 | Urine Colony Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 402 | MC4 | Urine Colony Count Combination | 1/EA | 1 | $ - 0 | $ - 0 |
| 403 | MC5 | Throat & Urine Cult/Rapid Strep A AG Det | 1/EA | 1 | $ - 0 | $ - 0 |
| 404 | ME | Monitoring Engraftment | 1/EA | 1 | $ - 0 | $ - 0 |
| 405 | MGL1 | CAP/ACMG Molecular Genetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 406 | MGL2 | CAP/ACMG Molecular Genetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 407 | MGL3 | CAP/ACMG Molecular Genetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 408 | MGL4 | CAP/ACMG Molecular Genetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 409 | MGL5 | CAP/ACMG Cystic Fibrosis | 1/EA | 1 | $ - 0 | $ - 0 |
| 410 | MHO | MHO, Lymphoma | 1/EA | 1 | $ - 0 | $ - 0 |
| 411 | MHO1 | MHO1, Lymphoma, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 412 | MHO2 | MHO2, Leukemia Only | 1/EA | 1 | $ - 0 | $ - 0 |
| 413 | MHO3 | MHO3, Leukemia Only, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 414 | MHO5 | DNA Extraction & Amplification FFPE | 1/EA | 1 | $ - 0 | $ - 0 |
| 415 | MK | Immunohistochemistry | 1/EA | 1 | $ - 0 | $ - 0 |
| 416 | MMA | MMA and Active B13 | 1/EA | 1 | $ - 0 | $ - 0 |
| 417 | MMR | DNA Mismatch Repair | 1/EA | 1 | $ - 0 | $ - 0 |
| 418 | MPA | Mycophenolic Acid | 1/EA | 1 | $ - 0 | $ - 0 |
| 419 | MRD | Minimal Residual Disease, BCR/ABL 1 p210 | 1/EA | 1 | $ - 0 | $ - 0 |
| 420 | MRD1 | Minimal Residual Disease, BCR/ABL 1 p190 | 1/EA | 1 | $ - 0 | $ - 0 |
| 421 | MRD2 | Minimal Residual Disease, PML/RARA | 1/EA | 1 | $ - 0 | $ - 0 |
| 422 | MRS | Methicillin Resistant S. aureus, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 423 | MRS2M | MRSA Screen, Molecular, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 424 | MRS5 | Methicillin Resistant S. aureus, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 425 | MRS5M | MRSA Screen, Molecular, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 426 | MSI | Microsatellite Instability | 1/EA | 1 | $ - 0 | $ - 0 |
| 427 | MTBR | Molecular MTB ID & Resistance Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 428 | MTP | Multigene Tumor Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 429 | MVM | Cerebrospinal Fluid, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 430 | MVP | Molecular Vaginal Panel | 1/EA | 1 | $ - 0 | $ - 0 |
| 431 | MX1B | HLA XMatch, Antibody Screen & ID (Class I) | 1/EA | 1 | $ - 0 | $ - 0 |
| 432 | MX1C | HLA XMatch, Antibody Screen & ID (Class I) | 1/EA | 1 | $ - 0 | $ - 0 |
| 433 | MX1E | HLA Antibody Screen & ID (Class I) | 1/EA | 1 | $ - 0 | $ - 0 |
| 434 | MX2B | HLA XMatch, Antibody Screen & ID (Class II) | 1/EA | 1 | $ - 0 | $ - 0 |
| 435 | MX2C | HLA Xmatch, Antibody Screen & ID (Class II) | 1/EA | 1 | $ - 0 | $ - 0 |
| 436 | MX2E | HLA Antibody Screen & ID (Class II) | 1/EA | 1 | $ - 0 | $ - 0 |
| 437 | MXB | MX1 / MX2 - MX1B/MX2B Combination, Class I & II | 1/EA | 1 | $ - 0 | $ - 0 |
| 438 | MXC | MX1 / MX2 - MX1C/MX2C Combination, Class I & II | 1/EA | 1 | $ - 0 | $ - 0 |
| 439 | MYG | Myoglobin, Urine | 1/EA | 1 | $ - 0 | $ - 0 |
| 440 | N | Urine Chemistry, Special | 1/EA | 1 | $ - 0 | $ - 0 |
| 441 | NAT | Nucleic Acid Testing | 1/EA | 1 | $ - 0 | $ - 0 |
| 442 | NB | Neonatal Bilirubin, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 443 | NB2 | Neonatal Bilirubin, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 444 | NEO | Neoplastic Cellularity | 1/EA | 1 | $ - 0 | $ - 0 |
| 445 | NGC | Interlab Comp Non-Gyn Cytology, Laboratory | 1/EA | 1 | $ - 0 | $ - 0 |
| 446 | NGC1 | Interlab Comp Non-Gyn Cytology, Individual | 1/EA | 2 | $ - 0 | $ - 0 |
| 447 | NGS | Next-Generation Sequencing - Germline | 1/EA | 1 | $ - 0 | $ - 0 |
| 448 | NGSB1 | NGS Bioinformatics forllumina | 1/EA | 1 | $ - 0 | $ - 0 |
| 449 | NGSB2 | NGS Bioinformatics for Ion Torrent | 1/EA | 1 | $ - 0 | $ - 0 |
| 450 | NGSBV | NGS Bioinformatics Somatic, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 451 | NGSE | NGS Undiagnosed Disorders - Exome | 1/EA | 1 | $ - 0 | $ - 0 |
| 452 | NGSHM | NGS Hematologic Malignancies | 1/EA | 1 | $ - 0 | $ - 0 |
| 453 | NGSST | NGS Solid Tumor | 1/EA | 1 | $ - 0 | $ - 0 |
| 454 | NIPT | Noninvasive Prenatal Testing | 1/EA | 1 | $ - 0 | $ - 0 |
| 455 | NOB | Novel Opioids and Benzodiazepines | 1/EA | 1 | $ - 0 | $ - 0 |
| 456 | NP | Neuropathology Program | 1/EA | 1 | $ - 0 | $ - 0 |
| 457 | NP1 | Neuropathology Program, Additional Pathologist | 1/EA | 1 | $ - 0 | $ - 0 |
| 458 | NTA | Nicotine and Tobacco Alkaloids | 1/EA | 1 | $ - 0 | $ - 0 |
| 459 | NX | Urine Chemistry - Special, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 460 | OCB | Occult Blood | 1/EA | 1 | $ - 0 | $ - 0 |
| 461 | OCBQ | Quality Cross Check—Occult Blood | 1/EA | 1 | $ - 0 | $ - 0 |
| 462 | OFD | Oral Fluid for Drugs of Abuse | 1/EA | 1 | $ - 0 | $ - 0 |
| 463 | OLI | CSF Chemistry w/Oligoclonal Bands | 1/EA | 1 | $ - 0 | $ - 0 |
| 464 | P | Parasitology | 1/EA | 1 | $ - 0 | $ - 0 |
| 465 | P16 | P16 Immunohistochemistry Tissue Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 466 | P3 | Parasite, Fecal Suspension, Immunoassay | 1/EA | 1 | $ - 0 | $ - 0 |
| 467 | P4 | Parasite, Fecal Suspension, PVA, Immunoassay | 1/EA | 1 | $ - 0 | $ - 0 |
| 468 | P5 | Parasitology, Giardia/Crypto Immunoassay | 1/EA | 1 | $ - 0 | $ - 0 |
| 469 | PAP PROG | PAP PT and Education Programs | 1/EA | 1 | $ - 0 | |
| 470 | PARF | Parentage/Relationship Test - Filter Paper | 1/EA | 1 | $ - 0 | $ - 0 |
| 471 | PCARI | Plasma Cardiac Markers International | 1/EA | 1 | $ - 0 | $ - 0 |
| 472 | PCARM | Plasma Cardiac Markers | 1/EA | 1 | $ - 0 | $ - 0 |
| 473 | PCARMX | Plasma Cardiac Markers, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 474 | PCNEO | Flow Cytometry - Plasma Cell Neoplasms | 1/EA | 1 | $ - 0 | $ - 0 |
| 475 | PCP1 | Pneumocystis, Calcofluor White Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 476 | PCP2 | Pneumocystis, DFA Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 477 | PCP4 | Pneumocystis, GMS Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 478 | PCT | Procalcitonin | 1/EA | 1 | $ - 0 | $ - 0 |
| 479 | PDL1 | PD-L1 | 1/EA | 1 | $ - 0 | $ - 0 |
| 480 | PEX | Expanded parasitology | 1/EA | 1 | $ - 0 | $ - 0 |
| 481 | PF | Platelet Aggregation | 1/EA | 1 | $ - 0 | $ - 0 |
| 482 | PF1 | Platelet Function | 1/EA | 1 | $ - 0 | $ - 0 |
| 483 | PGX | Pharmacogenetics | 1/EA | 1 | $ - 0 | $ - 0 |
| 484 | PGX1 | IL28B Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 485 | PGX2 | HLA Drug Hypersensitivity | 1/EA | 1 | $ - 0 | $ - 0 |
| 486 | PGX3 | DPYD, TPMT, UGT1A1 Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 487 | PHG | Plasma Hemoglobin | 1/EA | 1 | $ - 0 | $ - 0 |
| 488 | PIA | Drug-Specific Platelet Aggregation | 1/EA | 1 | $ - 0 | $ - 0 |
| 489 | PIAX | Drug-Specific Platelet Aggregation, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 490 | PIP | Performance Improvement Program in Surgical Pathology | 1/EA | 1 | $ - 0 | $ - 0 |
| 491 | PIP1 | Performance Improvement Program in Surgical Pathology, Additional Pathologist | 1/EA | 2 | $ - 0 | $ - 0 |
| 492 | PIPW | Online Performance Improvement Program, Surgical Pathology | 1/EA | 1 | $ - 0 | $ - 0 |
| 493 | PIPW1 | Online Performance Improvement Program, Surgical Pathology, Additional Pathologist | 1/EA | 1 | $ - 0 | $ - 0 |
| 494 | PLA | Lipoprotein-Associated Phospholipase A2 | 1/EA | 1 | $ - 0 | $ - 0 |
| 495 | PLTM | Platelet Mapping | 1/EA | 1 | $ - 0 | $ - 0 |
| 496 | PM1 | CD117, IHC Tissue Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 497 | PM2 | ER/PGR, IHC Tissue Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 498 | PM3 | CD20, IHC Tissue Microarray | 1/EA | 1 | $ - 0 | $ - 0 |
| 499 | PM5 | IHC Tissue Microarray Series | 1/EA | 1 | $ - 0 | $ - 0 |
| 500 | PM6 | Anaplastic Lymphoma Kinase IHC TMA | 1/EA | 1 | $ - 0 | $ - 0 |
| 501 | PNA1 | PNA for FISH for Staphylococcus | 1/EA | 1 | $ - 0 | $ - 0 |
| 502 | PNA2 | PNA for FISH for Yeast | 1/EA | 1 | $ - 0 | $ - 0 |
| 503 | PNH* | Flow PNH Immunophenotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 504 | POC1 | POC hCG Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 505 | POC2 | POC Glucose Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 506 | POC3 | POC Urine Dipstick Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 507 | POC4 | POC Strep Screen Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 508 | POC6 | POC PT/INR, CoaguChek XS+ Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 509 | POC7 | POC Waived Glucose & Hemoglobin Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 510 | POC8 | POC Influenza AB Antigen Detect Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 511 | POC9 | POC Fecal Occult Blood Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 512 | POC10 | POC Blood Gases Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 513 | POC11 | POC Blood Gases, i-STAT Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 514 | POC12 | POC Plasma Cardiac Markers Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 515 | POC14 | POC Medtronic ACT/ACT, i-STAT Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 516 | POC15 | POC Hemochron Jr IL GEM ACT-LR Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 517 | POC16 | POC Hemochron Jr Signature IL GEM Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 518 | PS | Platelet Serology | 1/EA | 1 | $ - 0 | $ - 0 |
| 519 | PTHQ | Quality Cross Check—Parathyroid Hormone | 1/EA | 1 | $ - 0 | $ - 0 |
| 520 | PV | Semen Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 521 | PV1 | Postvasectomy Sperm Count - Automated | 1/EA | 1 | $ - 0 | $ - 0 |
| 522 | QF | M. tuberculosis-Stimulated Infection Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 523 | QP191 | Technical Staffing Ratios | 1/EA | 1 | $ - 0 | $ - 0 |
| 524 | QP192 | Opioid Drug Testing Stewardship | 1/EA | 1 | $ - 0 | $ - 0 |
| 525 | QP193 | Expression Rates in Invasive Breast Carcinoma | 1/EA | 1 | $ - 0 | $ - 0 |
| 526 | QP194 | Impact of Pathologist Review of Peripheral Blood Smears | 1/EA | 1 | $ - 0 | $ - 0 |
| 527 | PRO | Four Q-PROBES Studies | 1/EA | 1 | $ - 0 | $ - 0 |
| 528 | QT1 | Patient Identification Accuracy | 1/EA | 1 | $ - 0 | $ - 0 |
| 529 | QT2 | Blood Culture Contamination | 1/EA | 1 | $ - 0 | $ - 0 |
| 530 | QT3 | Laboratory Specimen Acceptability | 1/EA | 1 | $ - 0 | $ - 0 |
| 531 | QT4 | Blood Product Wastage | 1/EA | 1 | $ - 0 | $ - 0 |
| 532 | QT5 | Gynecologic Cytology Outcomes | 1/EA | 1 | $ - 0 | $ - 0 |
| 533 | QT7 | Outpatient Satisfaction with Phlebotomy Service | 1/EA | 1 | $ - 0 | $ - 0 |
| 534 | QT8 | Stat Test Turnaround Time Outliers | 1/EA | 1 | $ - 0 | $ - 0 |
| 535 | QT10 | Critical Values Reporting | 1/EA | 1 | $ - 0 | $ - 0 |
| 536 | QT15 | Troponin Turnaround Times | 1/EA | 1 | $ - 0 | $ - 0 |
| 537 | QT16 | Corrected Results | 1/EA | 1 | $ - 0 | $ - 0 |
| 538 | QT17 | Outpatient Order Entry Errors | 1/EA | 1 | $ - 0 | $ - 0 |
| 539 | QTC | Clinical Pathology Monitors | 1/EA | 1 | $ - 0 | $ - 0 |
| 540 | QTP | CP/AP QTRACKS Monitors | 1/EA | 1 | $ - 0 | $ - 0 |
| 541 | R | Trace Metals | 1/EA | 1 | $ - 0 | $ - 0 |
| 542 | RAG | Red Blood Cell Antigen Genotyping | 1/EA | 1 | $ - 0 | $ - 0 |
| 543 | RAP | Renin and Aldosterone | 1/EA | 1 | $ - 0 | $ - 0 |
| 544 | RBCAT | Red Blood Cell Antigen Typing | 1/EA | 1 | $ - 0 | $ - 0 |
| 545 | RDS | Rheumatic Disease Special Serologies | 1/EA | 1 | $ - 0 | $ - 0 |
| 546 | RETT | CAP/ACMG Rett Syndrome (MECP2) | 1/EA | 1 | $ - 0 | $ - 0 |
| 547 | RF | Rheumatoid Factor | 1/EA | 1 | $ - 0 | $ - 0 |
| 548 | RFAV1 | Rare Flow Antigen Validation, CD1A | 1/EA | 1 | $ - 0 | $ - 0 |
| 549 | RFAV2 | Rare Flow Antigen Validation, CD103 | 1/EA | 1 | $ - 0 | $ - 0 |
| 550 | RFX | Rheumatoid Factor, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 551 | RHCVW | Anti-HCV, Rapid Methods, Waived | 1/EA | 1 | $ - 0 | $ - 0 |
| 552 | RMAL | Rapid Malaria | 1/EA | 1 | $ - 0 | $ - 0 |
| 553 | RNA | Fusion RNA | 1/EA | 1 | $ - 0 | $ - 0 |
| 554 | ROM1 | Rupture of Fetal Membranes | 1/EA | 1 | $ - 0 | $ - 0 |
| 555 | RT | Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 556 | RT2 | Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 557 | RT3 | Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 558 | RT3Q | Quality Cross Check—Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 559 | RT4 | Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 560 | RT4Q | Quality Cross Check—Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 561 | RTQ | Quality Cross Check—Reticulocyte | 1/EA | 1 | $ - 0 | $ - 0 |
| 562 | RUB | Rubella | 1/EA | 1 | $ - 0 | $ - 0 |
| 563 | RUBX | Rubella, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 564 | RUR | Rapid Urease | 1/EA | 1 | $ - 0 | $ - 0 |
| 565 | RVBN | Rivaroxaban Anticoagulant Monitoring | 1/EA | 1 | $ - 0 | $ - 0 |
| 566 | RWBC | Rapid Total Whole Blood Cell Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 567 | S2 | Immunology - Special | 1/EA | 1 | $ - 0 | $ - 0 |
| 568 | S4 | Immunology - Special, Limited | 1/EA | 1 | $ - 0 | $ - 0 |
| 569 | S5 | Immunology - Special, H. pylori IgG | 1/EA | 1 | $ - 0 | $ - 0 |
| 570 | SALC | Salivary Cortisol | 1/EA | 1 | $ - 0 | $ - 0 |
| 571 | SARC | Sarcoma Translocation | 1/EA | 1 | $ - 0 | $ - 0 |
| 572 | SBAS | S. pneumoniae Antigen Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 573 | SC | Sperm Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 574 | SC1 | Automated Sperm Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 575 | SCDD | Synthetic Cannabinoid/Designer Drugs | 1/EA | 1 | $ - 0 | $ - 0 |
| 576 | SCM1 | Urine Hemosiderin, Prussian Blue | 1/EA | 1 | $ - 0 | $ - 0 |
| 577 | SCM2 | Urine Eosinophils, Wright Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 578 | SCO | Serum Carryover | 1/EA | 1 | $ - 0 | $ - 0 |
| 579 | SCP | Stem Cell Processing | 1/EA | 1 | $ - 0 | $ - 0 |
| 580 | SCS | Sickle Cell Screening | 1/EA | 1 | $ - 0 | $ - 0 |
| 581 | SDS | Serum Drug Screening | 1/EA | 1 | $ - 0 | $ - 0 |
| 582 | SE | Diagnostic Allergy | 1/EA | 1 | $ - 0 | $ - 0 |
| 583 | SEC | CAP/ACMG DNA Sequencing Interpretation | 1/EA | 1 | $ - 0 | $ - 0 |
| 584 | SEC1 | CAP/ACMG DNA Sequencing Interpretation | 1/EA | 1 | $ - 0 | $ - 0 |
| 585 | SFLC | Serum Free Light Chains | 1/EA | 1 | $ - 0 | $ - 0 |
| 586 | SM | Sperm Morphology | 1/EA | 1 | $ - 0 | $ - 0 |
| 587 | SM1CD | Sperm Morphology on CD | 1/EA | 1 | $ - 0 | $ - 0 |
| 588 | SM2CD | Sperm Viability on CD | 1/EA | 1 | $ - 0 | $ - 0 |
| 589 | SMCD | Sperm Count and Motility on CD | 1/EA | 1 | $ - 0 | $ - 0 |
| 590 | SO | Blood Oximetry | 1/EA | 1 | $ - 0 | $ - 0 |
| 591 | SOQ | Quality Cross Check - Blood Oximetry | 1/EA | 1 | $ - 0 | $ - 0 |
| 592 | SP | Stool Pathogens | 1/EA | 1 | $ - 0 | $ - 0 |
| 593 | SP1 | Norovirus | 1/EA | 1 | $ - 0 | $ - 0 |
| 594 | SPE | Protein Electrophoresis | 1/EA | 1 | $ - 0 | $ - 0 |
| 595 | SPN | Stool Pathogen, without Shigatoxin | 1/EA | 1 | $ - 0 | $ - 0 |
| 596 | ST | Shiga Toxin | 1/EA | 1 | $ - 0 | $ - 0 |
| 597 | STFR | Soluble Transferrin Receptor | 1/EA | 1 | $ - 0 | $ - 0 |
| 598 | SV | Sperm Viability | 1/EA | 1 | $ - 0 | $ - 0 |
| 599 | SW1 | Sweat Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 600 | SW2 | Sweat Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 601 | SW3 | Sweat Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 602 | SW4 | Sweat Analysis | 1/EA | 1 | $ - 0 | $ - 0 |
| 603 | T | Toxicology | 1/EA | 1 | $ - 0 | $ - 0 |
| 604 | TBLA | Total Bile Acids | 1/EA | 1 | $ - 0 | $ - 0 |
| 605 | TEG | Viscoelastometry | 1/EA | 1 | $ - 0 | $ - 0 |
| 606 | THCB | Blood Cannabinoids | 1/EA | 1 | $ - 0 | $ - 0 |
| 607 | TICP | Touch Imprint/Crush Preparation | 1/EA | 1 | $ - 0 | $ - 0 |
| 608 | TICP1 | Touch Imprint/Crush Prep, Additional Participant | 1/EA | 1 | $ - 0 | $ - 0 |
| 609 | TM | Tumor Markers | 1/EA | 1 | $ - 0 | $ - 0 |
| 610 | TMCA | Transfusion Medicine Comprehensive - Competency Assessment | 1/EA | 1 | $ - 0 | $ - 0 |
| 611 | TMCAD | Direct Antiglobulin Test - Competency Assessment | 1/EA | 1 | $ - 0 | $ - 0 |
| 612 | TMCAE | Eluate Competency Assessment | 1/EA | 1 | $ - 0 | $ - 0 |
| 613 | TMCAF | Fetal Red Cell Quantitation - Competency Assessment | 1/EA | 1 | $ - 0 | $ - 0 |
| 614 | TMO | Ticks, Mites, and Other Arthropods | 1/EA | 1 | $ - 0 | $ - 0 |
| 615 | TMU | Trace Metals, Urine | 1/EA | 1 | $ - 0 | $ - 0 |
| 616 | TMWB | Trace Metals, Whole Blood | 1/EA | 1 | $ - 0 | $ - 0 |
| 617 | TMX | Tumor Markers, Double Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 618 | TNT | Troponin T, 2 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 619 | TNT5 | Troponin T, 5 Challenge | 1/EA | 1 | $ - 0 | $ - 0 |
| 620 | TPM | CAP/ACMG Thromophilia Mutations | 1/EA | 1 | $ - 0 | $ - 0 |
| 621 | TRC | Transfusion Related Cell Count | 1/EA | 1 | $ - 0 | $ - 0 |
| 622 | TTD | Tick Transmitted Disease | 1/EA | 1 | $ - 0 | $ - 0 |
| 623 | TVAG | T. vaginalis, Molecular | 1/EA | 1 | $ - 0 | $ - 0 |
| 624 | U | Urine Chemistry - General | 1/EA | 1 | $ - 0 | $ - 0 |
| 625 | UAA | Automated Urine Microscopy | 1/EA | 1 | $ - 0 | $ - 0 |
| 626 | UAA1 | Automated Urine Microscopy | 1/EA | 1 | $ - 0 | $ - 0 |
| 627 | UBJP | Urine Bence Jones Protein | 1/EA | 1 | $ - 0 | $ - 0 |
| 628 | UDC | CAP/AACC Forensic Urine Drug Test, Confirmatory | 1/EA | 1 | $ - 0 | $ - 0 |
| 629 | UDS | CAP/AACC Urine Drug Testing, Screening | 1/EA | 1 | $ - 0 | $ - 0 |
| 630 | UDS6 | CAP/AACC Urine Drug Testing, Screening, Ltd | 1/EA | 1 | $ - 0 | $ - 0 |
| 631 | UDSM | Urine Drug Testing, Screen, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 632 | UHCG | Urine hCG | 1/EA | 1 | $ - 0 | $ - 0 |
| 633 | UMC | Urine Albumin and Creatinine, Semiquant | 1/EA | 1 | $ - 0 | $ - 0 |
| 634 | UPBG | Porphobilinogen, Urine | 1/EA | 1 | $ - 0 | $ - 0 |
| 635 | URC | Urine Crystals | 1/EA | 1 | $ - 0 | $ - 0 |
| 636 | UT | Urine Toxicology | 1/EA | 1 | $ - 0 | $ - 0 |
| 637 | UTCO | Urine Toxicology Carryover | 1/EA | 1 | $ - 0 | $ - 0 |
| 638 | UVM | Urine Chemistry - General, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 639 | V | Viscosity | 1/EA | 1 | $ - 0 | $ - 0 |
| 640 | VBDM | Vector-Borne Disease - Molecular | 1/EA | 1 | $ - 0 | $ - 0 |
| 641 | VBF | Virtual Body Fluid | 1/EA | 1 | $ - 0 | $ - 0 |
| 642 | VBP | Virtual Biopsy Program | 1/EA | 1 | $ - 0 | $ - 0 |
| 643 | VBP1 | Virtual Biopsy Program, Additional Pathologist | 1/EA | 2 | $ - 0 | $ - 0 |
| 644 | VF | Vitreous Fluid, Postmortem | 1/EA | 1 | $ - 0 | $ - 0 |
| 645 | VGS1 | Virtual Gram Stain Basic Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 646 | VGS2 | Virtual Gram Stain Advanced Competency | 1/EA | 1 | $ - 0 | $ - 0 |
| 647 | VIP | Variant Interpretation Only | 1/EA | 1 | $ - 0 | $ - 0 |
| 648 | VIP1 | Variant Interpretation Only, Additional Participant | 1/EA | 1 | $ - 0 | $ - 0 |
| 649 | VITD | 25-OH Vitamin D, Total | 1/EA | 1 | $ - 0 | $ - 0 |
| 650 | VLS | BK, CMV, and EBV Viral Load | 1/EA | 1 | $ - 0 | $ - 0 |
| 651 | VLS2 | Viral Load | 1/EA | 1 | $ - 0 | $ - 0 |
| 652 | VM1 | Viral Markers - Series 1 | 1/EA | 1 | $ - 0 | $ - 0 |
| 653 | VM2 | Viral Markers - Series 2 | 1/EA | 1 | $ - 0 | $ - 0 |
| 654 | VM3 | Viral Markers - Series 3 | 1/EA | 1 | $ - 0 | $ - 0 |
| 655 | VM4 | Viral Markers - Series 4 | 1/EA | 1 | $ - 0 | $ - 0 |
| 656 | VM5 | Viral Markers - Series 5 | 1/EA | 1 | $ - 0 | $ - 0 |
| 657 | VM6 | Viral Markers - Series 6 | 1/EA | 1 | $ - 0 | $ - 0 |
| 658 | VM6X | Viral Markers - Series 6, Additional Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 659 | VPBS | Virtual Peripheral Blood Smear | 1/EA | 1 | $ - 0 | $ - 0 |
| 660 | VR1 | Virology Culture | 1/EA | 1 | $ - 0 | $ - 0 |
| 661 | VR2 | Virology Antigen Detection (DFA) | 1/EA | 1 | $ - 0 | $ - 0 |
| 662 | VR3 | Infectious Disease Serology | 1/EA | 1 | $ - 0 | $ - 0 |
| 663 | VR3M | Infectious Disease Serology, Mumps | 1/EA | 1 | $ - 0 | $ - 0 |
| 664 | VR4 | Virology Antigen Detection (Non-DFA) | 1/EA | 1 | $ - 0 | $ - 0 |
| 665 | VRE | Vancomycin-Resistant Enterococcus | 1/EA | 1 | $ - 0 | $ - 0 |
| 666 | VS | Vaginitis Screen Antigen Detection | 1/EA | 1 | $ - 0 | $ - 0 |
| 667 | VS1 | Vaginitis Screen, T. Vaginalis | 1/EA | 1 | $ - 0 | $ - 0 |
| 668 | VS2 | Vaginitis Screen, Virtual Gram Stain | 1/EA | 1 | $ - 0 | $ - 0 |
| 669 | WBCR | Whole Blood Creatinine | 1/EA | 1 | $ - 0 | $ - 0 |
| 670 | WBGQ | Quality Cross Check—Whole Blood Glucose | 1/EA | 2 | $ - 0 | $ - 0 |
| 671 | WID | Worm Identification | 1/EA | 1 | $ - 0 | $ - 0 |
| 672 | WP3 | Whole Blood PT/INR, I-STAT | 1/EA | 1 | $ - 0 | $ - 0 |
| 673 | WP4 | Whole Blood Citrated PT Hemochron/ IL GEM | 1/EA | 1 | $ - 0 | $ - 0 |
| 674 | WP6 | Whole Blood Non-Citrated PT Hemochron/ IL GEM | 1/EA | 1 | $ - 0 | $ - 0 |
| 675 | WP9 | Whole Blood Coagulation - CoaguChek, XS Plus | 1/EA | 1 | $ - 0 | $ - 0 |
| 676 | WP10 | Whole Blood Coagulation - CoaguChek XS System | 1/EA | 1 | $ - 0 | $ - 0 |
| 677 | Y | Ligand - Special | 1/EA | 1 | $ - 0 | $ - 0 |
| 678 | YVM | Ligand - Special, Validated Material | 1/EA | 1 | $ - 0 | $ - 0 |
| 679 | YY | Ligand - Special, Additional Volume | 1/EA | 1 | $ - 0 | $ - 0 |
| 680 | Z | TDM - General, Comprehensive | 1/EA | 1 | $ - 0 | $ - 0 |
| 681 | ZAP70 | ZAP-70/CD49D Analysis by Flow Cytometry | 1/EA | 1 | $ - 0 | $ - 0 |
| 682 | ZE | Therapeutic Drug Monitoring - Extended | 1/EA | 1 | $ - 0 | $ - 0 |
| 683 | ZT | Therapeutic Drug Monitoring - Special | 1/EA | 1 | $ - 0 | $ - 0 |
| 684 | APAPMPT1 | PAP PT ThinPrep W/ED Series 1, INDV | 1/EA | 4 | $ - 0 | $ - 0 |
| 685 | PAPMPT1 | PAP PT ThinPrep W/ED Series 1 | 1/EA | 1 | $ - 0 | $ - 0 |
| 686 | CAPBIND | CAP Generic Survey Binder | 1/EA | 12 | $ - 0 | $ - 0 |
| 687 | ESTIMATED FUEL SURCHARGE | 1/EA | 1 | $ - 0 | $ - 0 |
$ - 0
CAP PUBLICATIONS
2019 LABORATORY IMPROVEMENT PROGRAM ORDER FORM
| CAP NO. 221730101 Main Lab |
| CAP NO. 221730108 Anatomic Pathology |
| A/R NO. 22173100 |
| LINE | PROGRAM CODE | DESCRIPTION | QTY | UNIT PRICE | TOTAL |
| 1 | PUB100 | Autopsy: Aiding the Living by Understanding Death (packet of 50) | 1 | $ - 0 | $ - 0 |
| 2 | PUB115 | Handbook of Forensic Pathology, 2nd Edition | 1 | $ - 0 | $ - 0 |
| 3 | PUB119 | An Introduction to Autopsy Technique, 2nd Edition | 1 | $ - 0 | $ - 0 |
| 4 | PUB120 | Basic Competencies in Forensic Pathology: A Forensic Pathology Primer | 1 | $ - 0 | $ - 0 |
| 5 | PUB121 | CAP Practical Guide to Gynecologic Cytopathology | 1 | $ - 0 | $ - 0 |
| 6 | PUB122 | Special Autopsy Dissections | 1 | $ - 0 | $ - 0 |
| 7 | PUB123 | Histologic Preparations | 1 | $ - 0 | $ - 0 |
| 8 | PUB124 | Atlas of Transplant Pathology | 1 | $ - 0 | $ - 0 |
| 9 | PUB125 | Quality Management in Anatomic Pathology | 1 | $ - 0 | $ - 0 |
| 10 | PUB126 | Autopsy Performance & Reporting, 3rd Edition | 1 | $ - 0 | $ - 0 |
| 11 | PUB127 | Atlas of Fundamental Infectious Diseases Histopathology | 1 | $ - 0 | $ - 0 |
| 12 | PUB128 | Ultrasound Features of Superficial and Palpable Lesions | 1 | $ - 0 | $ - 0 |
| 13 | PUB213 | Color Atlas of Hemoglobin Disorders | 1 | $ - 0 | $ - 0 |
| 14 | PUB214 | Quality Management in Clinical Laboratories | 1 | $ - 0 | $ - 0 |
| 15 | PUB216 | Color Atlas of Body Fluids | 1 | $ - 0 | $ - 0 |
| 16 | PUB219 | Color Atlas of The Urinary Sediment | 1 | $ - 0 | $ - 0 |
| 17 | PUB220 | Clinical Toxicology Testing | 1 | $ - 0 | $ - 0 |
| 18 | PUB221 | Flow Cytometry in Evaluation of Hematopoietic Neoplasms | 1 | $ - 0 | $ - 0 |
| 19 | PUB222 | Color Atlas of Hematology, 2nd Edition | 1 | $ - 0 | $ - 0 |
| 20 | PUB223 | An Algorithmic Approach to Hemostasis Testing, 2nd Edition | 1 | $ - 0 | $ - 0 |
| 21 | PUB224 | Transfusion Medicine in The Hot Seat | 1 | $ - 0 | $ - 0 |
| 22 | PUB225 | So You're Going to Colelct a Blood Specimen: An Introduction to Phlebotomy, 15th Edition | 2 | $ - 0 | $ - 0 |
| 23 | PUB226 | Color Atlas of Mycology | 1 | $ - 0 | $ - 0 |
| 24 | PUB312 | Laboratory Administration for Pathologists | 1 | $ - 0 | $ - 0 |
| 25 | PUB313 | Atlas of Paleopathology | 1 | $ - 0 | $ - 0 |
| 26 | PUB314 | Developing and Organizing an Institutional Biospecimen Repository | 1 | $ - 0 | $ - 0 |
| 27 | PUB315 | The Health Art of Pathology | 1 | $ - 0 | $ - 0 |
| 28 | PUB316 | Patient Safety in Anatomic & Clinical Pathology Labs | 2 | $ - 0 | $ - 0 |
TOTAL: $ - 0
REFERENCE GUIDES
2019 LABORATORY IMPROVEMENT PROGRAM
| LINE | PROGRAM CODE | DESCRIPTION | QTY | UNIT PRICE | TOTAL |
| 1 | ABRG | Arthropod Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 2 | BFBRG | Body Fluids Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 3 | BMBRG | Bone Marrow Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 4 | GSBRG | Gram Stain Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 5 | HBRG | Hematology Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 6 | MBRG | Mycology Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 7 | PBRG | Parasitology Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 8 | SABRG | Semen Analysis Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
| 9 | UABRG | Urinalysis Benchtop Reference Guide | 1 | $ - 0 | $ - 0 |
TOTAL: $ - 0
ANNUAL FEE
2019 LABORATORY IMPROVEMENT PROGRAM
| LINE | PROGRAM CODE | DESCRIPTION | QTY | UNIT PRICE | TOTAL |
| 1 | CAP Annual Fee | 1 | $ - 0 | $ - 0 |
TOTAL: $ - 0
FUEL SURCHARGE
2019 LABORATORY IMPROVEMENT PROGRAM
| LINE | PROGRAM CODE | DESCRIPTION | QTY | UNIT PRICE | TOTAL |
| 1 | Fuel Surcharge | 1 | $ - 0 | $ - 0 |
TOTAL: $ - 0
File details come from the government source that posted it.